Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

ConclusionsThe safety profile of both schedules was acceptable, with QW dosing at the RP2D of 600  mg QW preferred for future clinical studies. Antitumor activity of tovorafenib inBRAF-mutated melanoma was promising and justifies continued clinical development across multiple settings.ClinicalTrials.gov identifierNCT01425008.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research